

[RELATED APPLICATIONS]

81 This application is a continuation-in-part of application Serial No. 08/795,962, filed February 6, 1997, now abandoned, which is a continuation of application Serial No. 08/586,427, filed January 16, 1996, now abandoned, which is a continuation of application Serial No. 08/215,030, filed March 18, 1994, now abandoned, which is a continuation-in-part of application Serial No. 08/033,385, filed March 18, 1993, now abandoned.]

In the Claims

Please cancel Claims 1, 11-14, 27, and 32 without prejudice or disclaimer.

Please amend the Claims in the following manner:

2. (Amended) The composition of Claim [1] 8, wherein the colloidal metal is selected from the group consisting of colloidal gold and colloidal silver.

92 3. (Amended) The composition of Claim [1] 8, wherein the biologically-active factor is a cytokine, a growth factor, a chemotherapeutic agent, a target molecule, a glycoprotein or a combination of biologically-active factors.

81 4. (Amended) The composition of Claim [1] 8, wherein the [immunologically toxic] biologically-active factor is selected from the group consisting of Interleukin-2 ("IL-2"), lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, Type I Interferon, Type II Interferon, Tumor Necrosis Factor, IL-1, IL-6, IL-[S]8, IL-4, Transforming Growth Factor-B, Lymphotoxin, IL-5, Migration Inhibition Factor, IL-3, Granulocyte Macrophage Colony-Stimulating Factor ("CSF"), Monocyte -Macrophage CSF, Granulocyte CSF, IL-7, IL-10, IL-11, IL-12, IL-13, vascular epithelial growth factor ("VEGF"), Angiogenin, transforming growth factor ("TGf α "), heat shock proteins, carbohydrate moieties of blood groups, Rh factors, hormones, receptors, DNA, [glucose], antibodies, and fibroblast growth factor.